Lytix Biopharma ASA has an expanding patent portfolio in the field of oncolytic peptides covering key markets throughout the world. The patent portfolio encompasses patents directed to design principles and production of oncolytic peptides, peptides per se, pharmaceutical compositions, medical uses and methods of treating tumours, including reshape of the tumor microenvironment and for inducing tumor specific immunity.